



FORM PTO-157 (Rev. 10/2006) A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/643,141

ATTY. DOCKET NO.: C1037.70049US00

FILING DATE: August 18, 2003

CONFIRMATION NO.: 3287

APPLICANT: Hutcherson et al.

GROUP ART UNIT: 1643

EXAMINER: David Harold Humphrey

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials ^a	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/AMG/		5,356,882		Walker et al.	10-18-1994
		5,877,309		McKay et al.	03-02-1999
		6,114,167		Symonds et al	09-05-2000
		6,399,630	B1	Macfarlane	06-04-2002
		6,653,292	B1	Krieg et al.	11-25-2003
		7,223,741	B2	Krieg	05-29-2007
		01-0044416	A1	McCluskie et al.	11-22-2001
		02-0165178	A1	Schetter et al.	11-07-2002
		02-0198165	A1	Bratzler et al.	12-26-2002
		03-0026782	A1	Krieg	02-02-2003
		03-0055014	A1	Bratzler	03-20-2003
		03-0166001	A1	Lipford	09-04-2003
		07-0129320	A9	Davis et al.	06-07-2007
		07-0142315	A1	Forsbach et al.	06-21-2007
		07-0184465	A1	Wagner et al.	08-09-2007
		07-0202128	A1	Krieg et al.	08-30-2007
		07-0224210	A1	Krieg et al.	09-27-2007
/AMG/		07-0232622	A1	Lipford et al.	10-04-2007

FOREIGN PATENT DOCUMENTS

Examiner's Initials ^a	Cite No.	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code		
/AMG/		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000
		WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000
		WO	06/080946	A2	Coley Pharmaceutical GMBH	08-03-2006
		WO	07/031877	A2	Coley Pharmaceutical GMBH	03-22-2007
/AMG/		WO	07/038720	A2	Coley Pharmaceutical GMBH	04-05-2007

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ^a	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/AMG/		BRANDA et al., Clin Immunol Immunopathol 1996, 79: 115-121	
		CROOKE, S. T., Therapeutic applications of oligonucleotides. Bio/technology, 1992: Vol. 10 No. 8, pages 882-886.	
		FLANAGAN et al., Nature Biotech. 17: 48-52 Jan. 1999	
		JONES T.R., et al. Vaccine 17: 3065-3071, 1999	
		KRIEG et al., Nat Revs, 2006 v5 p471	
		MCCLUSKIE M.J. et al., Vaccine 19: 2657-2660, 2001	
/AMG/		VOLLMER J. et al., Antisense and Nucleic Acid Drug Development 12: 165-172, 2002	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/643,141

ATTY. DOCKET NO.: C1037.70049US00

FILING DATE: August 18, 2003

CONFIRMATION NO.: 3287

APPLICANT: Hutcherson et al.

GROUP ART UNIT: 1643

EXAMINER: David Harold Humphrey

Sheet 2 of 2

/AMG/

WU CL et al. Anesthesiology 94: 1119-1132, 2001

EXAMINER:

/Anne M. Gussow/

DATE CONSIDERED:

02/11/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]